Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: ghmm who wrote (427)	10/4/2018 7:36:39 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 507

<If not I still think they shouldn't get involved in a public debate...> Great! Than tell me, how do you explain 3/15 RR in melanoma expansion cohort (20%, less than historical for Opdivo), and.or 5/15 RR in RCC expansion cohort (33%, less than historical for Opdivo)? Or, maybe should we left this for "SURPRISE PARTY"? When I am involved (long SH) with company, and when ANYONE bring legitimate question in regards the development candidate, I DO EXPECT company to defend tirelessly. I do not care what/how will SP react! I WANT EXPLANATION! So, I KNOW (or have feeling that I KNOW) what is going on! Long time ago (in 2001) I give up any efforts to communicate directly with any company. NEVER got strait answer on my question(s) (I do not ask for their health, nonetheless). Cheers, Miljenko